Flavopiridol HCl is primarily used in cancer research due to its potent inhibition of cyclin-dependent kinases (CDKs), which play a key role in cell cycle regulation. By blocking CDK activity, it interferes with the progression of cells through the division cycle, leading to the suppression of tumor cell proliferation. It has shown activity against a range of cancer types in preclinical studies, including leukemia, non-small cell lung cancer, and breast cancer. Its ability to induce apoptosis and inhibit transcription makes it a valuable tool in studying signaling pathways and developing targeted cancer therapies. Flavopiridol HCl has also been evaluated in clinical trials to assess its efficacy either as a single agent or in combination with other chemotherapeutics.